Aclidinium Bromide

阿地溴铵

Report date: 2026/05/25 20:02:40
NME

Base Information

Drug NameAclidinium Bromide
Drug Alias Namebromuro de aclidinio阿利溴铵bromure d’aclidiniumaclidinii bromidumEklira Genuair +[14] 
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionMuscarinic acetylcholine receptor M3 antagonists
TargetsMuscarinic acetylcholine receptor M3
Therapy Area/IndicationsPulmonary Disease, Chronic Obstructive
Global Approved IndicationsPulmonary Disease, Chronic Obstructive
Approved Indications in ChinaPulmonary Disease, Chronic Obstructive
Original Approved Country/TerritoryEU
Original Approved Date2012/07/20
Country/TerritoryCzechiaBelgiumBulgaria +[33] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesAlmirall Sa
China Registration ClassN/A

Develop Information

Active CompaniesCovis PharmaCovis Pharma Europe BVAstrazeneca Plc +[6] 
Inactive CompaniesDaewoong Pharmaceutical Co LtdAstrazeneca AbIndustrias Farmaceuticas Almirall Sa +[6] 
Active IndicationsPulmonary Disease, Chronic Obstructive
Inactive IndicationsN/A

Other Information

ATC CodeR03BB05
Related LinksWikipediaDrugBankKEGG